A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

S. Bellone, D. M. Roque, E. R. Siegel, N. Buza, P. Hui, E. Bonazzoli, A. Guglielmi, L. Zammataro, N. Nagarkatti, S. Zaidi, J. Lee, D. A. Silasi, G. S. Huang, V. Andikyan, S. Damast, M. Clark, M. Azodi, P. E. Schwartz, J. Tymon-Rosario, J. HaroldD. Mauricio, B. Zeybek, G. Menderes, G. Altwerger, E. Ratner, L. B. Alexandrov, A. Iwasaki, Y. Kong, E. Song, W. Dong, J. Elvin, J. Choi, A. D. Santin

Research output: Contribution to journalLetterpeer-review

28 Citations (Scopus)
Original languageEnglish
Pages (from-to)1045-1046
Number of pages2
JournalAnnals of Oncology
Volume32
Issue number8
DOIs
Publication statusPublished - 2021 Aug

Bibliographical note

Funding Information:
This work was supported in part by grants from the National Institutes of Health (NIH) [grant number U01 CA176067-01 ], the Tina Brozman Foundation , the Guido Berlucchi Foundation , and Gilead Sciences Inc . (no grant numbers), Foster City, CA to AS. This investigation was also supported by NIH Research Grant [grant number CA-16359 ] from the National Cancer Institute and Stand-Up-To-Cancer (SU2C) convergence grant 2.0 to AS.

Funding Information:
We would like to thank Merck USA for its industry support. This work was supported in part by grants from the National Institutes of Health (NIH) [grant number U01 CA176067-01], the Tina Brozman Foundation, the Guido Berlucchi Foundation, and Gilead Sciences Inc. (no grant numbers), Foster City, CA to AS. This investigation was also supported by NIH Research Grant [grant number CA-16359] from the National Cancer Institute and Stand-Up-To-Cancer (SU2C) convergence grant 2.0 to AS. The authors have declared no conflicts of interest.

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this